Nasdaq looks forward to helping you advance your listings efforts. At Nasdaq our “Modern Day IPO” process leverages data and technology to open IPOs electronically and remotely. Even when ...

Falling interest rates and crypto-friendly regulations are stirring talks of a crypto IPO boom. Explore the top crypto IPOs ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

IPO content provided by Renaissance Capital LLC, manager of the IPO-focused ETFs (tickers: IPO, IPOs).

Beta Bionics announced today that it went public after pricing a significantly upsized initial public offering (IPO).

Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million. The muted market ...

These are the upcoming IPOs (initial public offerings) for the week of February 3 to February 7, based on TipRanks’ IPO ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

Nasdaq reported higher fourth-quarter profit on Wednesday, helped by increased demand for the exchange operator's financial ...

Sports bar and restaurant chain Twin Peaks goes live on Nasdaq today. Inspire Brands and Panera Brands could be next in line ...

When US tech stocks were crushed by the emergence of DeepSeek this week, already-cautious investors found one more reason to ...

Beta Bionics hit net sales of $44.7m in the first nine months of 2024, marking an increase from $3.6m in 2023. Beta Bionics’ ...